A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors

Clinical Cancer Research

Volumn 14, Issue 20, 2008, Pages 6704-6711

  Tse, Archie N ^a,c   Klimstra, David S ^b   Gonen, Mithat ^b   Shah, Manish ^a   Sheikh, Tahir ^a   Sikorski, Rachel ^c   Carvajal, Richard ^a   Mui, Janet ^a   Tipian, Caroll ^a   O'Reilly, Eileen ^a   Chung, Ki ^a   Maki, Robert ^a   Lefkowitz, Robert ^b   Brown, Karen ^b   Manova Todorova, Katia ^c   Wu, Nian ^c   Egorin, Merrill J ^d   Kelsen, David ^a   Schwartz, Gary K ^a  

^a Departments of Preventive Medicine   (United States)

^b Department of Pathology ^*  (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 1; DRUG METABOLITE; HEAT SHOCK PROTEIN 90; IRINOTECAN; PROTEIN P53; TANESPIMYCIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; CAMPTOTHECIN; DRUG DERIVATIVE; MACROCYCLIC LACTAM; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CELL CYCLE G2 PHASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG SCREENING; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LIVER TOXICITY; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT; VOMITING; BLOOD; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; MIDDLE AGED; NEOPLASM; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 58149180924     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1006     Document Type: Article

References (23)

1. Solit DB, Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006;6:1205-14.
2. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldana- mycin results in cytostasis and apoptosis. Cancer Res 2001;61:4003-9.
3. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino- 17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-93.
4. Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res 2002;62:3132-7.
5. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharma-cokinetic and pharmaco dynamic studyof17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61.
6. Goetz MP, Toft D, Reid J, et al.Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87.
7. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385-91.
8. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advancedcancer. Clin Cancer Res 2007;13:1775-82.
9. Grem JL, Morrison G, Guo XD, et al. Phase I and pharma-cologic study of 17-(allylamino)-17-demethoxygeldana-mycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93.
10. Mesa RA, Loegering D, Powell HL, et al. Heat shock protein 90 in hibition sensitizesacute myelogenous leukemia cells to cytarabine. Blood 2005;106:318-27.
11. Arlander SJ, Eapen AK,Vroman BT, McDonald RJ, Toft DO, Karnitz LM. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 2003;278:52572-7.
12. Flatten K, Dai NT, Vroman BT, et al. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem 2005;280:14349-55.
13. Gonen M. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials. Contemp Clin Trials 2005;26: 131 -40.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
15. Bagatell R, Gore L, Egorin MJ, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-Nallylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 2007;13: 1783-8.
16. Yeh KC, Kwan KC. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm 1978;6:79-98.
17. Rocci ML, Jr., Jusko WJ. LAGRAN programforarea and moments in pharmacokinetic analysis. Comput ProgramsBiomed1983;16:203-16.
18. Rivory LP, Robert J. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr B Biomed Appl 1994;661: 133-41.
19. Banerji U, Walton M, Raynaud F, et al. Pharmacoki- netic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17- allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005;11:7023-32.
20. Tse A, Schwartz G. Potentiation of cytotoxicity of topoisomerase I poison by concurrent and sequential treatment with the checkpoint inhibitor 7-hydroxys-taurosporine involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res 2004;64:6635-44.
21. Modi S, Sugarman S, Stopeck A, et al. Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzu-mab (T) in patients (pts) with HER2-positive meta- static breast cancer (MBC). Proc Am Soc Clin Oncol 2008;26.
22. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008;13: 38-43.
23. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase1 in cancer therapeutics. Clin Cancer Res 2007;13:1955-60.